Drew Meyer is a director in the Life Sciences Consulting Group and leader of the group’s Investigations Consulting team. For more than 10 years, he has led corporate investigations for life sciences companies involving the Foreign Corrupt Practices Act ("FCPA"), False Claims Act (qui tam suits), and Anti-Kickback Statute. He possesses extensive experience in communicating with whistleblowers, conducting investigative interviews, and counseling client stakeholders on mitigation and remediation strategies resulting from investigations.

Prior to joining Paul Hastings, Mr. Meyer most recently served as global investigations director at Takeda Pharmaceuticals, where he was responsible for the Americas region, and as a global investigations lead at UCB Pharmaceuticals with global remit. Mr. Meyer also spent five years in China working for an investigations and crisis management consulting firm, where he led consulting teams in the provision of investigation services to life sciences companies in the areas of financial and accounting fraud, handling Code of Conduct violations, advising business compliance committees, and crisis management and response.

Mr. Meyer began his career in the Federal Bureau of Investigation, focusing on counterintelligence issues. He speaks and reads Mandarin Chinese at a professional level.  Mr. Meyer provides advisory services.